drugset / Trial / NCT03322735
Study of BCMA CAR-T in Multiple Myeloma
Phase 1/2
Unknown
10 enrolled
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Timeline
- Start
- 2017-12-08
- Primary completion
- 2018-10
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |